Investigational drug · Phase 3
MG-K10
Also called: Humanized Monoclonal Antibody
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
5 still active
All registered trials
738
Any phase or sponsor naming "MG-K10"
First trial start
2024
Jul 19, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MG-K10", any sponsor or status.
Conditions studied
As listed on its trial records.
- Dermatitis, Atopic
- Chronic Urticaria, Idiopathic
- Atopic Dermatitis
- Asthma
- Chronic Rhinosinusitis With Nasal Polyps
- Atopic Dermatitis (AD)
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Chronic hives (urticaria) · Asthma · Immunology and inflammation · Respiratory · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "MG-K10" as an intervention, largest first.
- Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and EffectivenessPivotal-lookingRecruiting
Insud PharmaIndustry
NCT06282315 · 20,000 participants (planned) · Start Sep 1, 2025 · Primary completion Apr 2026
Drug: Pre-screening Phase; Screenig Phase and 6 more · For: Soil-Transmitted Helminths
Sites: Accra, Ghana; Nairobi, Kenya
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
Centro Neurológico de Pesquisa e Reabiitação, BrazilAcademic, hospital or other
NCT03147092 · 15,000 participants (planned) · Start Feb 1, 2018 · Primary completion Jun 30, 2020
Drug: Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,; Atenolol and 2 more · For: Hypertension; Blood Pressure
- Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in SepsisPivotal-lookingCompleted
Children's Hospital of PhiladelphiaAcademic, hospital or other
NCT04102371 · 9,041 participants · Start Aug 25, 2020 · Primary completion Dec 1, 2025
Drug: Lactated Ringer; Normal Saline and 1 more · For: Shock; Septic
Sites: Davis, California; Los Angeles, California; San Francisco, California · 22 sites in all
- Helicobacter Pylori Eradication and Follow-upStatus unknown
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT05061732 · 4,447 participants (planned) · Start Sep 30, 2021 · Primary completion Jun 30, 2026
Drug: Rabeprazole; Bismuth potassium citrate and 7 more · For: Helicobacter Pylori Infection
Sites: Shanghai, China
- A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe PneumoniaPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT04041791 · 4,392 participants · Start Aug 19, 2019 · Primary completion Apr 5, 2024
Drug: Benzyl penicillin; Gentamicin Sulfate and 3 more · For: Pneumonia
Sites: Machakos, Kenya
- Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00090259 · 3,834 participants · Start Dec 19, 2001 · Primary completion Mar 31, 2009
Drug: Losartan 50 mg; Losartan 150 mg · For: Heart Failure
- Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic FunctionPivotal-lookingCompleted
Carelon ResearchAcademic, hospital or other
NCT00094302 · 3,445 participants · Start Aug 2006 · Primary completion Jun 2013
Drug: Spironolactone; Placebo · For: Cardiovascular Diseases; Heart Diseases; Heart Failure, Congestive
Sites: Birmingham, Alabama; Glendale, Arizona; Phoenix, Arizona · 270 sites in all
- Study of Contraceptive Efficacy & Safety of Phexxi™ (Previously Known as Amphora) Gel Compared to Conceptrol Vaginal GelPivotal-lookingCompleted
Evofem Inc.Industry
NCT01306331 · 3,389 participants · Start Apr 2011 · Primary completion Jun 2014
Drug: Conceptrol; Amphora · For: Contraception
Sites: Birmingham, Alabama; Little Rock, Arkansas; Anaheim, California · 52 sites in all
- Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic TherapyPivotal-lookingRecruiting
Duk-Woo Park, MDAcademic, hospital or other
NCT04416581 · 3,320 participants (planned) · Start May 12, 2021 · Primary completion Dec 31, 2027
Drug: PPI; P-CAB 50 · For: Coronary Artery Disease; Percutaneous Coronary Intervention; Acute Coronary Syndrome and 1 more
Sites: Anyang, South Korea; Bucheon-si, South Korea; Busan, South Korea · 45 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Safety signals of tocilizumab in pediatric patients: A real-world pharmacovigilance analysis based on the FAERS database with network pharmacology insights.
Wu G, Ma X, Zhu B, et al. · Hum Vaccin Immunother 2026
- Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trial.
van Lier D, Mourisse L, Hollander H, et al. · MAbs 2026
- Revisiting Daclizumab for Multiple Sclerosis: A Systematic Evaluation of a Targeted Immunotherapy.
Naghdi Y, Azhari Rad R, Keshavarzian M, et al. · Immunopharmacol Immunotoxicol 2026
- Structural basis of QX007N neutralizing interleukin-33 for asthma and COPD treatment.
Wang Q, Ke H, Wu Y, et al. · Structure 2026
- SHR-2004, a Humanized Monoclonal Antibody Targeting Factor XI, for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active-Controlled Phase 2 Study.
Jiang G, Tang J, Zhao H, et al. · Am J Hematol 2026
Also in development for Dermatitis, Atopic
- CamoteskimabAPL-9109Phase 22 trials
Apollo Therapeutics Ltd · Atopic Dermatitis, Atopic, Dermatitis
- JNJ-95597528Phase 22 trials
Johnson & Johnson (Janssen) · Dermatitis, Atopic, Asthma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.